Insider Selling: Alnylam Pharmaceuticals, Inc. Sells 1,750 Shares of Regulus Therapeutics Stock (RGLS)
Regulus Therapeutics (NASDAQ:RGLS) major shareholder Alnylam Pharmaceuticals, Inc. sold 1,750 shares of Regulus Therapeutics stock on the open market in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $7.04, for a total transaction of $12,320.00. Following the transaction, the insider now directly owns 6,093,400 shares of the company’s stock, valued at approximately $42,897,536. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Separately, analysts at FBR Capital Markets raised their price target on shares of Regulus Therapeutics from $14.00 to $15.00 in a research note on Thursday, August 7th. They now have an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $16.50.
Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down 0.85% during mid-day trading on Friday, hitting $7.02. 31,571 shares of the company’s stock traded hands. Regulus Therapeutics has a 52 week low of $5.40 and a 52 week high of $11.88. The stock has a 50-day moving average of $6.94 and a 200-day moving average of $7.94. The company’s market cap is $304.6 million.
Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.29) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.19) by $0.10. On average, analysts predict that Regulus Therapeutics will post $-1.01 earnings per share for the current fiscal year.
Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.